Navigation Links
Telik Announces Third Quarter 2012 Financial Results
Date:11/9/2012

PALO ALTO, Calif., Nov. 9, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported a net loss of $1.9 million, or $0.78 per share, for the third quarter ended September 30, 2012, compared with a net loss of $2.8 million, or $1.58 per share (adjusted for the 1-for-30 reverse split of the company's common stock effected on March 30, 2012), for the comparable period in 2011.

For the quarter ended September 30, 2012, total operating costs and expenses were $1.9 million, compared with $2.9 million in the third quarter of 2011. Operating expenses in the 2012 third quarter included stock-based compensation expense of approximately $0.1 million. Operating expenses were approximately 34% lower in the third quarter of 2012 compared with the same period in 2011, primarily due to lower headcount, corporate and stock-based compensation expenses.

For the nine months ended September 30, 2012, Telik reported a net loss of $6.2 million, or $3.07 per share, compared with a net loss of $9.5 million, or $5.30 per share, for the same period in 2011.  Total operating expenses for the first nine months of 2012 were $6.2 million, compared with $9.6 million for the same period in 2011. Operating expenses in the first nine months of 2012 included approximately $0.6 million in stock-based compensation expense. The reduction in operating expenses of approximately 35% in the first nine months of 2012 compared with the same period in 2011 was primarily due to lower headcount, reduced clinical trial expenses, and lower corporate and stock-based compensation expenses.

At September 30, 2012, Telik had $6.6 million in cash, cash equivalents and investments including restricted investments, compared to $11.7 million at December 31, 2011. In order to meet its current cash requirements beyond the first quarter of 2013, the company will have to raise additional funds through corporate partnering or equity financings. Although the company has been able to raise funds through its At Market Issuance Sales Agreement, there is no assurance Telik will be successful in obtaining additional funding in the near future.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic disorders including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.Telik, Inc.Statements of Operations(In thousands, except per share amounts)(Unaudited)Three Months Ended Nine Months EndedSeptember 30,September 30,2012201120122011Operating costs and expenses:Research and development 

$
867$
,305$
2,788$
4,464General and administrative 

1,0111,5503,4235,090Total operating costs and expenses

1,8782,8556,2119,554Loss from operations

(1,878)(2,855)(6,211)(9,554)Interest and other income (expense), net

27631Net loss

$
(1,876)$
(2,848)$
(6,205)$
(9,523)Basic and diluted net loss per share*

$
(0.78)$
(1.58)$
(3.07)$
(5.30)Weighted average shares used to calculate basic and diluted net loss per share*

2,3951,7992,0211,796* Adjusted for the 1-for-30 reverse stock splitSelected Balance Sheet Data(In thousands)(Unaudited)September 30,December 31,20122011Cash, cash equivalents, investments and restricted investments

$
,642$
,700Total assets

7,44512,412Stockholders' equity

4,6278,299
'/>"/>

SOURCE Telik, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
2. Cannabis Science Provides Corporate Guidance on Preclinical Initiatives and Recent Corporate Developments for its Shareholders; CBIS Announces plans for 1st Q of 2013 Webinar Investor Call
3. Array BioPharma Announces Pricing Of Public Offering Of Common Stock
4. IntelliCell BioSciences Announces FDA Registration for its Cell Processing Facility
5. NxStage Announces Fourth Quarter 2012 Investor Conference Schedule
6. Unilife Corporation Announces Financial Results For Fiscal Year 2013 First Quarter
7. Array BioPharma Announces Proposed Public Offering Of Common Stock
8. Allscripts Announces Third Quarter 2012 Results
9. Jazz Pharmaceuticals Announces Third Quarter 2012 Results
10. Protalex, Inc. Announces Screening Of First Patients In U.S. For New Trial Of PRTX-100 In Patients With Active Rheumatoid Arthritis
11. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)...  As the latest Obamacare repeal effort moves is ... (R-LA) and Lindsey Graham (R-SC) medical device ... industry is in an odd place.  The industry wants ... tax on medical device sales passed along with the ... increased visits and hospital customers with the funding to ...
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
(Date:9/13/2017)... OrthoAtlanta has been named the official orthopedic and sports ... the 2018 College Football Playoff (CFP) National Championship to be ... Atlanta, Georgia . OrthoAtlanta is proud to ... in many activities leading up to, and including the national ... OrthoAtlanta ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor ... on sciatica in a new episode of "Success Files," which is an award-winning ... innovation and investigates each subject in-depth with passion and integrity. , Sciatica occurs ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... New Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... fitness centers in the U.S., announced today its plans to open a flagship location ... club will occupy the former Rooms To Go store next to Office Depot in ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Mohebi Hair Restoration, has recently contributed a medical article to the newly revamped ... cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular ...
Breaking Medicine News(10 mins):